COVID-19 3rd Dose Vaccine in Transplant Patients

A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients

The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.

Inclusion Criteria:

• Patients 18 years of age and older
• Patients who had received a solid organ (kidney, liver, lung, heart, and pancreas) transplant patient from living or deceased donors.
• Patients with active graft with at least one immunosuppressive medication
• Completed two doses of BNT162b2 vaccination at least 28 days ago

Exclusion Criteria:

• Patient with non-active graft
• Any significant side effect with previous COVID-19 vaccination
• Within 28 days of BNT162b2 vaccine completion
• Already received more than and equal to three doses of COVID-19 vaccination
• Previously received COVID-19 vaccine other than BNT162b2 vaccine
• Previously received monoclonal Antibody treatment that are specifically directed against the spike protein for Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV)-2 such as Mab, Bamlanivimab, etesevimab, Casirivimab, imdevimab, Sotrovimab and/or any combination.
• Thrombocytopenia (if less than 50,000 per microliter 30 days prior vaccination)
• History of Capillary Leak Syndrome
• Adults unable to consent
• Individuals who are not yet adults (younger than 18 year old)
• Vulnerable patients (prisoners)
• Pregnant women